OLDWICK, N.J., March 5, 2020 /PRNewswire/ -- Provention
Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical
company dedicated to intercepting and preventing immune-mediated
disease, today announced that it will report its fourth quarter and
full year 2019 financial results on Thursday, March 12, 2020.
In connection with the earnings release, Provention's management
team will host a live conference call and webcast at 8:30 AM ET on
Thursday, March 12, 2020, to discuss
the Company's financial results and provide a corporate update.
Conference Call Information
To access the call, please
dial 1-877-870-4263 (domestic) or 1-412-317-0790 (international)
five minutes prior to the start time and ask to be connected to the
"Provention Bio Call". An audio webcast will also be available in
the "Events and Webcasts" page in the Investors page of the
Company's website, www.proventionbio.com. An archived webcast
will be available on the Company's website approximately two hours
after the conference call and will be available for 30 days
following the call.
About Provention Bio, Inc.
Provention Bio, Inc.
(Nasdaq: PRVB) is a clinical-stage biopharmaceutical company
leveraging a transformational drug development strategy focused on
the prevention or interception of immune-mediated disease.
Provention's mission is to source, transform and develop
therapeutic candidates targeting the high morbidity, mortality and
escalating costs of autoimmune diseases. Provention's diversified
portfolio includes PRV-031 (teplizumab), a pre-commercial-stage
candidate that has been shown to delay the onset of end-stage type
one diabetes (T1D) in at-risk individuals with pre-symptomatic
disease. Teplizumab has been granted Breakthrough Therapy
designation from the U.S. Food and Drug Administration. The
company's portfolio includes additional clinical-stage product
development candidates that have
demonstrated proof-of-mechanism and/or proof-of-concept
in other autoimmune diseases, including celiac disease and
lupus.
Investors:
Sam Martin, Argot Partners
sam@argotpartners.com
212-600-1902
Media:
David Rosen, Argot Partners
david.rosen@argotpartners.com
212-600-1902
View original content to download
multimedia:http://www.prnewswire.com/news-releases/provention-bio-to-report-fourth-quarter-and-full-year-2019-financial-results-and-host-conference-call-on-thursday-march-12-2020-301016897.html
SOURCE Provention Bio, Inc.